Nanoparticle application in diabetes drug delivery
Source abstract
Abstract
The management of diabetes, in contrast to the treatment of the disease, is basically aimed at controlling the blood glucose level. Besides the primary changes required in the lifestyle and diet of the patient, drug therapy can play a critical role in the diabetes management. Diabetic drugs are formulated in various forms to permit oral, transdermal, internasal, or delivery by subcutaneous injection. Notably, in formulations intended for controlled release, targeted delivery, and those requiring protection of the therapeutic agent, nanoparticles (NPs) play a crucial role. Nanoparticle-based drug formulations can also alleviate the common side effects associated with the regular administration of pure drugs. In this review, we will consider the impact of NPs on the delivery of both oral and injectable drugs to manage diabetes as well as the potential application of nanotechnology to the development of devices such as microneedles aimed at improving the delivery of diabetes drugs.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Diabetes Management and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (63)
Show source-provided references
1. Hu M, Cherkaoui I, Misra S, Rutter GA (2020) Functional genomics in pancreatic β cells: recent advances in gene deletion and genome editing technologies for diabetes research. Front Endocrinol 1110.3389/fendo.2020.576632 ↗
2. Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R (2015) Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discovery 14:4510.1038/nrd4477 ↗
3. Hussain T, Tan B, Murtaza G, Liu G, Rahu N, Kalhoro MS, Kalhoro DH, Adebowale TO, Mazhar MU, urRehman Z (2020) Flavonoids and type 2 diabetes: evidence of efficacy in clinical and animal studies and delivery strategies to enhance their therapeutic efficacy. Pharmacol Res 152:10462910.1016/j.phrs.2020.104629 ↗
4. Sarmah S, Pahari S, Belwal VK, Jana M, Roy AS (2020) Elucidation of molecular interaction of bioactive flavonoid luteolin with human serum albumin and its glycated analogue using multi-spectroscopic and computational studies. J Mol Liq 318:11414710.1016/j.molliq.2020.114147 ↗
5. Qiu H, Jin L, Chen J, Shi M, Shi F, Wang M, Li D, Xu X, Su X, Yin X (2020) Comprehensive glycomic analysis reveals that human serum albumin glycation specifically affects the pharmacokinetics and efficacy of different anticoagulant drugs in diabetes. Diabetes 69:760–77010.2337/db19-0738 ↗
6. Hörber S, Achenbach P, Schleicher E, Peter A (2020) Harmonization of immunoassays for biomarkers in diabetes mellitus. Biotechnol Adv 39:10735910.1016/j.biotechadv.2019.02.015 ↗
7. Zhang Y, Li J, Wu M, Guo Z, Tan D, Zhou X, Li Y, Liu S, Xue L, Lei Y, (2020) Glucose-responsive gold nanocluster-loaded microneedle patch for type 1 diabetes therapy. ACS Appl Bio Mater10.1021/acsabm.0c01042 ↗
8. Dovc K, Battelino T (2020) Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes. Expert Opin Drug Deliv 17:157–16610.1080/17425247.2020.1713747 ↗
9. Zamboni F, Collins MN (2017) Cell based therapeutics in type 1 diabetes mellitus. Int J Pharm 521:346–35610.1016/j.ijpharm.2017.02.063 ↗
10. Yamada Y, Tabata M, Yasuzaki Y, Nomura M, Shibata A, Ibayashi Y, Taniguchi Y, Sasaki S, Harashima H (2014) A nanocarrier system for the delivery of nucleic acids targeted to a pancreatic beta cell line. Biomaterials 35:6430–643810.1016/j.biomaterials.2014.04.017 ↗
11. Wu M, Liao L, Jiang L, Zhang C, Gao H, Qiao L, Liu S, Shi D (2019) Liver-targeted nano-MitoPBN normalizes glucose metabolism by improving mitochondrial redox balance. Biomaterials 222:11945710.1016/j.biomaterials.2019.119457 ↗
12. Kazemi F, Divsalar A, Saboury AA, Seyedarabi A (2019) Propolis nanoparticles prevent structural changes in human hemoglobin during glycation and fructation. Colloids Surf, B 177:188–19510.1016/j.colsurfb.2019.01.046 ↗
13. Lakkireddy HR, Urmann M, Besenius M, Werner U, Haack T, Brun P, Alié J, Illel B, Hortala L, Vogel R (2016) Oral delivery of diabetes peptides—comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. Adv Drug Deliv Rev 106:196–22210.1016/j.addr.2016.02.011 ↗
14. Sharma G, Sharma AR, Nam J-S, Doss GPC, Lee S-S, Chakraborty C (2015) Nanoparticle based insulin delivery system: the next generation efficient therapy for type 1 diabetes. J Nanobiotechnol 13:7410.1186/s12951-015-0136-y ↗
15. Sharma R, Gupta U, Garg NK, Tyagi RK, Jain N (2015) Surface engineered and ligand anchored nanobioconjugate: an effective therapeutic approach for oral insulin delivery in experimental diabetic rats. Colloids Surf, B 127:172–18110.1016/j.colsurfb.2015.01.035 ↗
16. Jayakrishnapillai P, Nair SV, Kamalasanan K (2017) Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes. Colloids Surf, B 153:123–13110.1016/j.colsurfb.2017.02.017 ↗
17. Dungan K, DeSantis A, (2016) Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus, Up to date Nov, 21
18. Chen Y, Li Y, Shen W, Li K, Yu L, Chen Q, Ding J (2016) Controlled release of liraglutide using thermogelling polymers in treatment of diabetes. Sci Rep 6:3159310.1038/srep31593 ↗
19. Tahrani AA, Barnett AH, Bailey CJ (2016) Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12:56610.1038/nrendo.2016.86 ↗
20. Li L, Jiang G, Yu W, Liu D, Chen H, Liu Y, Tong Z, Kong X, Yao J (2017) Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers for oral delivery of insulin. Mater Sci Eng, C 70:278–28610.1016/j.msec.2016.08.083 ↗
21. Shamsi A, Ahmed A, Khan MS, Husain FM, Bano B, (2020) Rosmarinic acid restrains protein glycation and aggregation in human serum albumin: multi spectroscopic and microscopic insight-possible therapeutics targeting diseases. Int J Biol Macromol10.1016/j.ijbiomac.2020.06.048 ↗
22. AlBab ND, Hameed MK, Maresova A, Ahmady IM, Arooj M, Han C, Workie B, Chehimi M, Mohamed AA (2020) Inhibition of amyloid fibrillation, enzymatic degradation and cytotoxicity of insulin at carboxyl tailored gold-aryl nanoparticles surface. Colloids Surf, A 586:12427910.1016/j.colsurfa.2019.124279 ↗
23. Shilo M, Berenstein P, Dreifuss T, Nash Y, Goldsmith G, Kazimirsky G, Motiei M, Frenkel D, Brodie C, Popovtzer R (2015) Insulin-coated gold nanoparticles as a new concept for personalized and adjustable glucose regulation. Nanoscale 7:20489–2049610.1039/C5NR04881H ↗
24. Wu S, Bin W, Tu B, Li X, Wang W, Liao S, Sun C (2019) A delivery system for oral administration of proteins/peptides through bile acid transport channels. J Pharm Sci 108:2143–215210.1016/j.xphs.2019.01.027 ↗
25. Wu L, Bai Y, Wang L, Liu X, Zhou R, Li L, Wu R, Zhang Z, Zhu X, Huang Y (2020) Promoting apical-to-basolateral unidirectional transport of nanoformulations by manipulating the nutrient-absorption pathway. J Control Release10.1016/j.jconrel.2020.04.013 ↗
26. Chen Y, Shan X, Luo C, He Z (2020) Emerging nanoparticulate drug delivery systems of metformin. J Pharm Investig 1–1210.1007/s40005-020-00480-1 ↗
27. Baig MMFA, Abbas M, Naveed M, Kassim SA, Khan GJ, Sohail M, Ullah S, Hasnat M, Shah K, Ansari MT (2019) Design, synthesis and evaluation of DNA nano-cubes as a core material protected by the alginate coating for oral administration of anti-diabetic drug. J Food Drug Anal 27:805–81410.1016/j.jfda.2019.03.004 ↗
28. Fang X, Yang T, Wang L, Yu J, Wei X, Zhou Y, Wang C, Liang W (2016) Nano-cage-mediated refolding of insulin by PEG-PE micelle. Biomaterials 77:139–14810.1016/j.biomaterials.2015.11.007 ↗
29. Zhang Y, Li J, Wang Z, Xu M-Z, Zeng Z, Huang J-P, Guan Y-Q (2020) Natural plant-derived polygalacturonic acid-oleanolic acid assemblies as oral-delivered nanomedicine for insulin resistance treatment. Chem Eng J 124630.10.1016/j.cej.2020.124630 ↗
30. Hu X, Yu J, Qian C, Lu Y, Kahkoska AR, Xie Z, Jing X, Buse JB, Gu Z (2017) H2O2-responsive vesicles integrated with transcutaneous patches for glucose-mediated insulin delivery. ACS Nano 11:613–62010.1021/acsnano.6b06892 ↗
31. Yu J, Zhang Y, Yan J, Kahkoska AR, Gu Z (2018) Advances in bioresponsive closed-loop drug delivery systems. Int J Pharm 544:350–35710.1016/j.ijpharm.2017.11.064 ↗
32. Mohammadpour F, Hadizadeh F, Tafaghodi M, Sadri K, Mohammadpour AH, Kalani MR, Gholami L, Mahmoudi A, Chamani J (2019) Preparation, in vitro and in vivo evaluation of PLGA/chitosan based nano-complex as a novel insulin delivery formulation. Int J Pharm 572:11871010.1016/j.ijpharm.2019.118710 ↗
33. Sharma D, Arora S, Singh J (2019) Smart thermosensitive copolymer incorporating chitosan–zinc–insulin electrostatic complexes for controlled delivery of insulin: effect of chitosan chain length. Int J Polym Mater PolymBiomater 1–1510.1080/00914037.2019.1655750 ↗
34. Seo B-B, Park M-R, Song S-C (2019) Sustained release of exendin 4 using injectable and ionic-nano-complex forming polymer hydrogel system for long-term treatment of type 2 diabetes mellitus. ACS Appl Mater Interfaces 11:15201–1521110.1021/acsami.8b19669 ↗
35. Gilroy CA, Luginbuhl KM, Chilkoti A (2016) Controlled release of biologics for the treatment of type 2 diabetes. J Control Release 240:151–16410.1016/j.jconrel.2015.12.002 ↗
36. Schwenk RW, Baumeier C, Finan B, Kluth O, Brauer C, Joost H-G, DiMarchi RD, Tschöp MH, Schürmann A (2015) GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 58:604–61410.1007/s00125-014-3478-3 ↗
37. Saatchi K, Tod SE, Leung D, Nicholson KE, Andreu I, Buchwalder C, Schmitt V, Häfeli UO, Gray SL (2017) Characterization of alendronic-and undecylenic acid coated magnetic nanoparticles for the targeted delivery of rosiglitazone to subcutaneous adipose tissue, Nanomedicine: Nanotechnology. Bio Med 13:559–568
38. Xu B, Jiang G, Yu W, Liu D, Liu Y, Kong X, Yao J (2017) Preparation of poly (lactic-co-glycolic acid) and chitosan composite nanocarriers via electrostatic self assembly for oral delivery of insulin. Mater Sci Eng, C 78:420–42810.1016/j.msec.2017.04.113 ↗
39. Omid NJ, Javan NB, Dehpour A-R, Partoazar A, Tehrani MR, Dorkoosh F (2018) In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. Int J Pharm 535:293–30710.1016/j.ijpharm.2017.11.020 ↗
40. Zhang Y, Zhang L, Ban Q, Li J, Li C-H, Guan Y-Q (2018) Preparation and characterization of hydroxyapatite nanoparticles carrying insulin and gallic acid for insulin oral delivery, Nanomedicine: Nanotechnology. Biol Med 14:353–364
41. Kozuka C, Shimizu-Okabe C, Takayama C, Nakano K, Morinaga H, Kinjo A, Fukuda K, Kamei A, Yasuoka A, Kondo T (2017) Marked augmentation of PLGA nanoparticle-induced metabolically beneficial impact of γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice. Drug Deliv 24:558–56810.1080/10717544.2017.1279237 ↗
42. Fullagar B, Rao W, Gilor C, Xu F, He X, Adin CA (2017) Nano-encapsulation of bilirubin in pluronic F127–chitosan improves uptake in β cells and increases islet viability and function after hypoxic Stress. Cell Transpl 26:1703–171510.1177/0963689717735112 ↗
43. Maiti S, Mukherjee S, Datta R (2014) Core–shell nano-biomaterials for controlled oral delivery and pharmacodynamic activity of glibenclamide. Int J Biol Macromol 70:20–2510.1016/j.ijbiomac.2014.06.031 ↗
44. Baig MMFA, Khan S, Naeem MA, Khan GJ, Ansari MT (2018) Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus. Biomed Pharmacother 97:1250–125810.1016/j.biopha.2017.11.059 ↗
45. Varanko AK, Chilkoti A (2019) Molecular and materials engineering for delivery of peptide drugs to treat type 2 diabetes. Adv Healthcare Mater 8:180150910.1002/adhm.201801509 ↗
46. Cho EY, Ryu J-Y, Lee HAR, Hong SH, Park HS, Hong KS, Park S-G, Kim HP, Yoon T-J (2019) Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. J Nanobiotech 17:1910.1186/s12951-019-0452-8 ↗
47. Rabiei M, Kashanian S, Samavati SS, Jamasb S, McInnes SJ (2019) Nanomaterial and advanced technologies in transdermal drug delivery. J Drug Target 1–1210.1080/1061186X.2019.1693579 ↗
48. Ye Y, Yu J, Wen D, Kahkoska AR, Gu Z (2018) Polymeric microneedles for transdermal protein delivery. Adv Drug Deliv Rev 127:106–11810.1016/j.addr.2018.01.015 ↗
49. Yu J, Wang J, Zhang Y, Chen G, Mao W, Ye Y, Kahkoska AR, Buse JB, Langer R, Gu Z, (2020) Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs. Nat Biomed Eng 1–810.1530/ey.17.10.12 ↗
50. Rabiei M, Kashanian S, Bahrami G, Derakhshankhah H, Barzegari E, Samavati SS, McInnes SJ (2021) Dissolving microneedle-assisted long-acting liraglutide delivery to control type 2 diabetes and obesity. Eur J Pharm Sci 167:10604010.1016/j.ejps.2021.106040 ↗
51. Chen G, Yu J, Gu Z (2019) Glucose-responsive microneedle patches for diabetes treatment. J Diabetes Sci Technol 13:41–4810.1177/1932296818778607 ↗
52. Zhang Y, Wang J, Yu J, Wen D, Kahkoska AR, Lu Y, Zhang X, Buse JB, Gu Z (2018) Bioresponsive microneedles with a sheath structure for H2O2 and pH cascade-triggered insulin delivery. Small 14:170418110.1002/smll.201704181 ↗
53. Tong Z, Zhou J, Zhong J, Tang Q, Lei Z, Luo H, Ma P, Liu X (2018) Glucose-and H2O2-responsive polymeric vesicles integrated with microneedle patches for glucose-sensitive transcutaneous delivery of insulin in diabetic rats. ACS Appl Mater Interfaces 10:20014–2002410.1021/acsami.8b04484 ↗
54. Yu J, Qian C, Zhang Y, Cui Z, Zhu Y, Shen Q, Ligler FS, Buse JB, Gu Z (2017) Hypoxia and H2O2 dual-sensitive vesicles for enhanced glucose-responsive insulin delivery. Nano Lett 17:733–73910.1021/acs.nanolett.6b03848 ↗
55. Wang J, Ye Y, Yu J, Kahkoska AR, Zhang X, Wang C, Sun W, Corder RD, Chen Z, Khan SA (2018) Core–shell microneedle gel for self-regulated insulin delivery. ACS Nano 12:2466–247310.1021/acsnano.7b08152 ↗
56. Xu B, Jiang G, Yu W, Liu D, Zhang Y, Zhou J, Sun S, Liu Y (2017) H 2 O 2-responsive mesoporous silica nanoparticles integrated with microneedle patches for the glucose-monitored transdermal delivery of insulin. J Mater Chem B 5:8200–820810.1039/C7TB02082A ↗
57. Fu Y, Liu P, Chen M, Jin T, Wu H, Hei M, Wang C, Xu Y, Qian X, Zhu W (2022) On-demand transdermal insulin delivery system for type 1 diabetes therapy with no hypoglycemia risks. J Colloid Interface Sci 605:582–59110.1016/j.jcis.2021.07.126 ↗
58. Chen W, Tian R, Xu C, Yung BC, Wang G, Liu Y, Ni Q, Zhang F, Zhou Z, Wang J (2017) Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy. Nat Commun 8:1–1110.1038/s41467-017-01764-1 ↗
59. Hu W, Su Y-W, Jiang Y-K, Fan W-D, Cheng S-Y, Tong Z-Z, Cen C, Jiang G-H (2022) Polymer vesicles with upper critical solution temperature for near-infrared light-triggered transdermal delivery of metformin in diabetic rats. Chin J Polym Sci 40:157–16510.1007/s10118-021-2640-x ↗
60. Tsou YH, Wang B, Ho W, Hu B, Tang P, Sweet S, Zhang XQ, Xu X (2019) Nanotechnology-mediated drug delivery for the treatment of obesity and its related comorbidities. Adv Healthcare Mater 8:180118410.1002/adhm.201801184 ↗
61. Zhang Y, Liu Q, Yu J, Yu S, Wang J, Qiang L, Gu Z (2017) Locally induced adipose tissue browning by microneedle patch for obesity treatment. ACS Nano 11:9223–923010.1021/acsnano.7b04348 ↗
62. trial NCT 02827094 (i.e. enhanced epidermal antigen specific immunotherapy trial -1 EE-ASI-1
63. Dul M, Nikolic T, Stefanidou M, McAteer M, Williams P, Mous J, Roep B, Kochba E, Levin Y, Peakman M (2019) Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. Int J Pharm 562:303–31210.1016/j.ijpharm.2019.03.041 ↗